Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa
The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial. RV-001 a gene-agnostic approach for RP patients. TOKYO, Feb. 13, 2025 /PRNewswire/ -- Restore...
Aker Horizons ASA: Fourth-quarter results 2024
FORNEBU, Norway, Feb. 13, 2025 /PRNewswire/ -- Aker Horizons ASA (OSE: AKH), a developer of green energy and industry, today announced results for the fourth quarter 2024. Aker Horizons' net capital employed stood at NOK 5.9 billion, a decrease of...
Cloud4C Secures Dual AI Specializations on Microsoft Azure, Strengthening AI Capabilities
SINGAPORE, Feb. 13, 2025 /PRNewswire/ -- Cloud4C, a global leader in AI-driven cloud and cybersecurity services, has achieved two prestigious AI specializations on Microsoft Azure: 'AI Platform on Microsoft Azure' and 'Build AI Apps on Microsoft...
Hugel achieves record net sales, profit, net income in 2024
- The company reports KRW373.0 billion in net sales, KRW166.3 billion in operating profit, and KRW142.4 billion in net income, reflecting year-over-year increases of 16.7%, 41.2%, and 45.8%, respectively - More international revenue contributions to...
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a...
Woolpert Welcomes Head of Strategic Growth, Asia-Pacific Susie Henderson
The accomplished global business executive will oversee the firm's strategic growth initiatives for the Asia-Pacific region. BRISBANE, Australia, Feb. 13, 2025 /PRNewswire/ -- Woolpert has hired Susie Henderson as Head of Strategic Growth,...
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
SUZHOU, China, Feb. 13, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug...
Polyplastics Launches New Eco-friendly PLASTRON (R) ︎LFT with Reduced Weight, Higher Rigidity, and Strong Damping
TOKYO, Feb. 13, 2025 /PRNewswire/ -- Polyplastics Co., Ltd., a global leader in engineering plastics, has launched PLASTRON (R) LFT (long fiber-reinforced thermoplastic) RA627P, an eco-friendly composite of polypropylene (PP) resin and long...